Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.

Discovery of cysteine-targeting covalent histone methyltransferase inhibitors

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Chemical inhibitors targeting histone methylation readers

Histone lysine methyltransferases as anti-cancer targets for drug discovery

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Epigenetic targets and drug discovery: part 1: histone methylation.

Recent Advances in Targeting Histone H3 Lysine 36 Methyltransferases for Cancer Therapy

Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Histone Methyltransferases: Novel Targets for Tumor and Developmental Defects.

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Protein Lysine Methyltransferases Inhibitors

Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)

Deciphering the interplay of histone post-translational modifications in cancer: Co-targeting histone modulators for precision therapy

Research Progress in Inhibitors of Histone Methyltransferase G9a

Research progress in histone lysine demethylases inhibitors

Structural Simulation and Selective Inhibitor Discovery Study for Histone Demethylases KDM4E/6B from a Computational Perspective